Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $9 to $7.
Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $9 to $7.